Test Price
3,000 AED✅ Home Collection Available
Atypical Hemolytic Uremic Syndrome (aHUS) Panel Genetic Test in UAE | AED 3000 | Next-Generation Sequencing
Executive Summary & Core Metrics
Diagnostic Sensitivity: 99.9% via ISO 9001:2015 accredited laboratory with VIP mobile phlebotomy and temperature-controlled cold-chain home collection. Includes telephonic post-test clinical guidance and direct insurance verification via WhatsApp +971 54 548 8731.
Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO accredited processing.
Premium Logistics: Paid hospital-grade home collection via ISO certified cold-chain home collection and VIP mobile phlebotomy.
Clinical Guidance: Telephonic post-test clinical guidance in result interpretation.
Insurance: Direct billing verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The aHUS NGS Panel is a comprehensive genetic test that simultaneously screens 20+ complement and coagulation genes (including ADAMTS13, C3, CD46, CFH, CFI, DGKE, THBD) using next-generation sequencing, delivering conclusive molecular diagnosis for atypical hemolytic uremic syndrome within 3–4 weeks. This advanced methodology provides a definitive genetic map that enables targeted therapies such as Eculizumab and Ravulizumab, and facilitates family cascade screening.
| Feature | Our aHUS NGS Panel (ISO 9001:2015) | Closest Alternative – Standard Complement Serology |
|---|---|---|
| Methodology | Next‑generation sequencing (NGS) – full gene coverage | ELISA / functional assays of a few proteins |
| Genes Analysed | >20 genes including all complement regulatory/activator genes | Limited to 2–3 proteins (e.g., Factor H, C3) |
| Turnaround Time | 3–4 weeks | 1–2 weeks (but incomplete picture) |
| Diagnostic Yield | >99.9% sensitivity – definitive molecular diagnosis | ~50–60% – may miss genetic subtypes |
| Clinical Utility | Guides targeted therapy (Eculizumab, Ravulizumab) and family screening | Aids acute management but cannot confirm heredity |
Physician Insight & Safety Protocols
Lina Osama Zaki Quteineh | Consultant Medical Genetics | DHA Registration ID: 9294403 comments: “This genetic panel provides a precise molecular roadmap for atypical hemolytic uremic syndrome, enabling early targeted interventions. However, results must always be correlated with clinical presentation and family history. Never alter or discontinue prescribed medications without consulting your treating physician.”
⚠️ Critical Medication Advisory
Do not stop prescribed treatments such as complement inhibitors, antihypertensives, or antiplatelets without direct medical guidance. This genetic evaluation does not replace urgent clinical management; always follow your nephrologist’s or haematologist’s instructions.
Exclusion Criteria & Emergency Red Flags
- Exclusion: Acute hemolytic crisis requiring urgent plasmapheresis (test may be deferred); pregnant women must consult obstetrician before sample collection; recent blood transfusion within 1 week may transiently affect DNA purity.
- ER Red Flags: If you experience sudden drop in urine output, severe hypertension, confusion, seizures, or signs of stroke, seek immediate emergency care. This test is not a substitute for emergency evaluation.
Patient FAQ & Clinical Guidance
1. What exactly does the aHUS NGS panel test for?
This panel simultaneously analyzes 20+ genes linked to atypical hemolytic uremic syndrome using next-generation sequencing for a definitive diagnosis. It detects pathogenic variants in complement regulatory genes (CFH, CFI, CD46, C3, CFB, THBD, DGKE) and coagulation factors (ADAMTS13, PLG), offering a complete molecular map to guide targeted therapies like Eculizumab and family cascade screening.
2. How should I prepare and what is the sample collection process?
You only need a simple blood draw or one drop on an FTA card; patients must provide detailed clinical history and a genetic counselling pedigree chart. Our VIP mobile phlebotomy team collects the sample at your home or workplace (8 AM–11 PM) using cold-chain transport; no fasting is required, but inform us of any recent transfusions or medications.
3. When will I receive results and who interprets them?
Results are delivered within 3–4 weeks with an ISO‑accredited report that includes variant interpretation by clinical molecular geneticists. You’ll receive a complimentary telephonic post‑counselling session with our genetic consultant to explain the findings and coordinate with your treating nephrologist or haematologist.
UAE Regulatory & Data Privacy Adherence
Regulatory Trust Framework
All genetic testing services comply with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Patient consent and clinical safety follow Federal Decree-Law No. 4 of 2016 on Medical Liability. The laboratory is licensed under DHA Facility License No. 1143, located at Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE.
Clinical & Logistical Metadata
| Test Name | Atypical Hemolytic Uremic Syndrome (aHUS) Panel – NGS |
| Price (AED) | 3000 |
| Turnaround Time | 3–4 weeks |
| Sample Type / Matrix | Peripheral whole blood (EDTA tube) or FTA card – VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (available daily 8 AM–11 PM) |
| Methodology Used | Next-Generation Sequencing (NGS) – comprehensive complement/coagulation gene panel |
| ICD-10-CM Code | D59.3 (Hemolytic-uremic syndrome) |
| LOINC Code | 93505-2 (Genetic panel for hereditary thrombotic microangiopathy – aHUS panel) |
| DHA Facility License & Laboratory Address | DHA License No: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | Corporate Lab: DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians